Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07032792 · ClinicalTrials.gov registry record · Phase 2
Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery
A Phase 2 study of Surgery and Cardiac Disease, sponsored by Northwell Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT07032792: Recruiting Phase 2 study of Surgery and Cardiac Disease, sponsored by Northwell Health.
NCT07032792 is a Phase 2 study of Surgery and Cardiac Disease that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 140 participants, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07032792, a Phase 2 study of Surgery and Cardiac Disease, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
Coagulopathic-induced bleeding after cardiopulmonary bypass in cardiac surgery patients is common and is associated with adverse outcomes in cardiac surgery. The hypothesis of the study is that FEIBA will be a more effective treatment than standard of care (FFP) in cardiac surgery patients who have coagulopathic-induced bleeding. This study is being conducted to determine the efficacy of FEIBA versus FFP as first line therapy in correcting coagulopathic induced microvascular bleeding in cardiac surgery patients.
Conditions Studied
Interventions
- DRUG FEIBA
- DRUG FFP
Study Locations (1)
New York
- North Shore University Hospital - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2029-11 |
| Phase | Phase 2 |
What NCT07032792 shows while recruiting
NCT07032792 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Surgery appearing as the primary indexed condition, and to 2 interventions - of which FEIBA is the first listed.
NCT07032792 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07032792 about?
NCT07032792 is a clinical study titled "Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery". Coagulopathic-induced bleeding after cardiopulmonary bypass in cardiac surgery patients is common and is associated with adverse outcomes in cardiac surgery. The hypothesis of the study is that FEIBA will be a more effective treatment than standard of care (FFP) in cardiac surgery patients who have ...
What is the current status of trial NCT07032792?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-11-03. Estimated completion is 2029-11.
What conditions does trial NCT07032792 study?
This clinical trial studies the following conditions: Surgery, Cardiac Disease, Bleeding.
What interventions are being tested in trial NCT07032792?
The interventions under investigation include: FEIBA (DRUG), FFP (DRUG).
Who is sponsoring clinical trial NCT07032792?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07032792 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07032792's enrollment target sits among peer trials
140 49th of 120 higher than 72 of 120 other Surgery trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Surgery trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prevent Cardiac Surgery Associated AKI Trial
RECRUITING · Phase 2
-
A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery
RECRUITING · Phase 2
-
Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription
COMPLETED · Phase 2
-
Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
COMPLETED · Phase 2
-
Terumo Aortic Global Endovascular Registry
RECRUITING
-
A Study of the Use of 3D Technology to Guide Head and Neck Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI